F]fluoro-L-ascorbic acid (
18 F-DFA, Fig. 1 ) as a positron-labeled analog of ascorbic acid for studying oxidative damages in vivo by positron emission tomography (PET). Tissue distribution studies in normal rats or tumor-bearing mice demonstrated that the uptake and distribution pattern of 18 F-DFA has a remarkable resemblance to that reported for [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]ascorbate, with preferential uptake in the adrenal glands and slow brain uptake kinetics. [3] [4] [5] Recently, Monnier et al. used DFA for studying the mechanism in experimental diabetes with 19 F-NMR spectroscopy, showing that DFA is a very powerful tool for the clarification of ascorbate homeostasis and catabolism in vivo. 6) However, whether 18 F-DFA is a suitable radiolabeled ascorbate analog for studying the biology of ascorbate uptake and accumulation in vivo by PET remains unclear.
The tripeptide glutathione (GSH) is part of an integrated antioxidant system that protects cells and tissues from oxidative damage and its imbalance is observed in a wide range of pathologies, including cancer and neurological disorders. 7) It has also been shown that there are significant interactions between GSH and ascorbate as exemplified by the physiologic recycling of ascorbate. 8, 9) To clarify the relationship between the tissue accumulation and distribution of 18 F-DFA and intracellular GSH content, we studied 18 F-DFA accumulation in vivo in diethyl maleate-induced GSH-deficient rats together with that of L- [1- 14 C]ascorbic acid ( 14 C-AA) for direct comparison. We also discuss the mechanisms underlying the sensitivity of 18 F-DFA accumulation to GSH depletion in vivo.
MATERIALS AND METHODS
Diethyl maleate (DEM) was purchased from nacalai tesque (Kyoto, Japan). L-[1- GBq/mmol) with a radiochemical purity of Ͼ98% was prepared as previously described.
3) All other reagents used were of analytical grade and were obtained from commercial sources. All experiments were carried out in male Wistar rats which were fed on a normal diet and given water ad libitum. All animal experiments were carried out in accordance with Faculty Regulations on animal experiments of the Faculty of Pharmaceutical Sciences, Kyushu University. DEM Treatment and Tissue GSH Concentration Male Wistar rats (215-300 g) were given a single injection of different doses of DEM (6.2, 4.7 and 3.1 mmol/kg) intraperitoneally, using peanut oil as a diluent. Control rats (210-218 g) were injected with the vehicle of peanut oil alone.
At 2 h after DEM or peanut oil alone injection, each rat was killed by cervical dislocation while under ether anesthesia. The excised tissues (100-150 mg) were homogenized in 5% sulfosalicylic acid (5 ml) on ice. After centrifugation at 3000 g for 10 min, the supernatant (ca. 200 ml) was diluted up to 10-fold with an ice-cold phosphate-EDTA buffer, which consisted of 100 mM Na 2 HPO 4 and 5 mM EDTA, pH 7. Concentrations of total glutathione (GSHϩGSSG) were measured in another set of DEM-treated and control rats, using a glutathione reductase-5,5Ј-dithio bis(2-nitrobenzoic acid)-based enzymatic recycling assay, according to the method described by Tietze, 10) in which the absorbance change at 412 nm in the final assay mixture was continuously monitored for 3 min with a JASCO V-550 UV/VIS spectrometer. The GSH concentration in the present report is denoted as total glutathione (GSHϩGSSG). 18 F-DFA, the accumulation of radioactivity in most tissues, including the adrenal glands, liver and brain, was significantly reduced together with a decrease in the content of GSH by preloading of diethyl maleate (DEM) which depletes cellular GSH. Similar decreased uptake was also observed in the distribution of L-[1-pH 6.0), with activities ranging from 1.42-0.48 MBq, were injected through the tail vein of unanesthetized rats subjected to the DEM treatment. At 120 min postinjection the animals were killed under ether anesthesia. Samples of blood and organs including various brain regions were removed, blotted free of blood, and weighed. The brain regions were dissected into 11 discrete regions. Radioactivity levels were determined by a Packard auto-gamma 500 scintillation counter (corrected for decay). In another experiment, the controls (peanut oil injection) were also subjected to the 18 F-DFA distribution studies as described above.
Biodistribution C-AA) in about 0.5 ml saline containing 0.4 mM DL-homocysteine, with activities ranging from 74.9-63.9 kBq, were injected through the tail vein of unanesthetized rats. The rats were sacrificed at 2 h postinjection, and samples of blood and organs including various brain regions were removed. After weighing, samples of blood (100 ml) and tissues (50-100 mg) were digested at 60°C overnight in screw-capped counting vials containing 1 ml of NCS tissue solubilizer (Amersham, Buckinghamshire U.K.). The tissues were completely dissolved. Coloration was removed by bleaching with benzoyl peroxide in toluene (500 ml for blood; 300 ml for tissue) at 60°C for 30 min.
After the addition of 10 ml of scintillator liquid (ACS II), the samples were left at room temperature in a dark room for 1 h. Radioactivity measurements were performed with a liquid scintillation counter (LSC-3500, Aloka Tokyo Japan). The controls (peanut oil injection) were also subjected to 14 C-AA uptake studies as described above. Ascorbic Acid Concentration in Blood Plasma Blood, from each DEM-treated or control rat, 4 h after the treatment, was collected and blood plasma was prepared by centrifugation for 5 min at 2000 rpm. The plasma was then used either for immediate analysis or stored at Ϫ20°C under an argon atmosphere until the time of the assay for ascorbic acid. The ascorbic acid concentration in the blood plasma was measured according to the method described by Zannoni et al., 11) in which the ferric ion was reduced by ascorbic acid and the ferrous ion-a,aЈ-dipyridyl complex was measured spectrophotometrically at 525 nm.
Statistical Analysis All values are expressed as the meanϮS.E.M. Lack of significant difference using the Student's t-test was considered to be pϾ0.05.
RESULTS AND DISCUSSION
Glutathione-Deficient Rats Diethyl maleate (DEM), an agent known to conjugate directly with GSH, acts to deplete intracellular GSH in tissue with glutathione S-transferase activity. [12] [13] [14] In this study, GSH deficiency was produced in Wistar rats by a single intraperitoneal administration of different doses (3.1 mmol/kg and 6.2 mmol/kg) of DEM. As shown in Table 1 , DEM depleted the GSH levels in all examined tissues in a dose-dependent manner after 2 h from time of treatment had lapsed, consistent with the data reported in the literature. 14) Hepatic and adrenal GSH concentrations fell to 4% and 26% of the control levels, respectively, at a dose of 6.2 mmol/kg of DEM. At a higher dose of DEM, the level of all brain GSH was found to have decreased with reduction of 60% of control levels and a more marked decrease of GSH concentration was found in the cerebral cortex, thalamus and hypothalamus.
Biodistribution Studies The biodistribution of 18 F-DFA and 14 C-AA was investigated in GSH-deficient rats at 2 h after tracer injection. This time point was chosen because it is one at which the brain level approached that of the blood after 18 F-DFA injection, as was found in our earlier experiment, [3] [4] [5] and also a marked lowering of tissue GSH concentrations during 2-4 h after DEM injection (4.6 mmol/kg) was observed in the rats.
14) The tissue radioactivity levels were calculated as a percentage of the injected dose per gram of tissue for each DEM-treated group and control group of rats treated with the vehicle. We also utilized the uptake ratio of tissue-to-blood as an additional indicator of specificity and The biodistribution in DEM-treated rats for both radiotracers demonstrates a significant decreased uptake of radioactivity in the peripheral tissues such as the liver, adrenal glands and heart as well as brain regions such as the thalamus and hypothalamus, in comparison with vehicle-treated control rats, as shown in Tables 2, 3 . On the other hand, substantially higher levels of radioactivity in the GSH-depleted rats, compared with the control rats, were seen only in the blood, and for both radiotracers. The extent of decreased tissue accumulation under GSH-depleted conditions was similar for both radiotracers. The tissue GSH content and tissue-to-blood ratio of 18 F-DFA showed a positive correlation only in the liver and whole brain, as shown in Fig. 2 , including an additional result obtained at a dose of 4.7 mmol/kg of DEM. In other tissues, no distinct positive correlation could be visualized.
Mechanistic Consideration The present study demonstrates that a decrease in tissue GSH induced by DEM led to a substantial decrease in the ability of 18 F-DFA as well as 14 C-AA to accumulate into tissues. Several possibilities can be conceived to explain the biological mechanism responsible for these results. First of all, simple alteration of blood flow by DEM treatment was considered negligible. This assumption is supported by in vivo study using 99m Tc-d,l-HMPAO, an agent for measuring regional cerebral blood flow, in which DEM administration in rats did not interfere with cerebral uptake of the radiotracer. 15) In the present study, chemical identification of the accumulated 18 F-radioactivity into tissues was not examined. However, in our previous study which used rat brain exposed to postischemic reperfusion, 19 F-NMR spectroscopic analysis showed that DFA remained intact in the brain after injection of DFA. 5) Moreover, a study by Monnier et al. 6) on the metabolic fate of DFA has demonstrated that in the liver, brain and adrenal glands, more than 80% of fluorine-containing compounds after injection were present in reduced form in both normal and diabetic rats. Therefore, we consider that the accumulated 18 F-activity into tissues primarily reflects the uptake and accumulation of 18 F-DFA itself. The mechanism of AA accumulation varies in different tissues. AA and its oxidized product, dehydroascorbic acid (DHA), have distinct transport pathways, mediated by sodium-dependent ascorbate transporters (SVCT1 and SVCT2) and sodium-independent glucose transporters (GLUTs), respectively, both of which produce intracellular accumulation of AA. SVCT1 is most often found in epithelial cells such as those of the intestine and kidney, whereas SVCT2, expressed by neuroepithelial cells of the choroid plexus, allows concentrations in the brain. [16] [17] [18] It has been shown that DFA is a competitive inhibitor of sodium-dependent ascorbate transporters with an inhibition constant K i of 32 mM, which is slightly higher than that (K i ϭ16 mM) of AA itself. 19) In view of those data, it appears likely that, in vivo, 18 F-DFA is regulated by the same mechanism as that involved in the transport and accumulation of AA.
Oxidative stress caused by GSH depletion is known to lead to substantial damage in tissues together with various biochemical and molecular abnormalities. 20) It is possible that the ability to transport ascorbic acid by different cells may be regulated by the expression level of the specific transporter and by regulation of its activity. Thus, if acute DEM exposure could cause alterations in the expression of and/or affinity for the transporter of AA, tissue GSH deficiency as a result of DEM treatment might affect tissue accumulation of 18 F-DFA or 14 C-AA. However, such interaction is unknown at present and this hypothesis seems to be less probable.
Increased AA levels have been found in the liver early in GSH deficiency of adult mice and rats, capable of de novo AA synthesis and thereby AA is available to other tissues and cell transporters via circulation. 21) In our complementary experiments, the mean AA levels of blood plasma in DEMtreated rats (6.2 mmol/kg DEM) was found to be 2.78Ϯ 0.14 mg/dl, which was significantly greater than that in con- trol (Table 4 ). This finding may give an indication that the observed decrease in tissue accumulation of both 18 
